Inclusion Criteria:

          -  Subjects must have confirmation of Acute Myeloid Leukemia (AML) by WHO criteria and be
             ineligible for treatment with a standard cytarabine and anthracycline induction
             regimen due to co-morbidity or other factors.

          -  Subject must have received no prior treatment for AML with the exception of
             hydroxyurea

          -  Subjects must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0
             to 2 for subjects greater than or equal to 75 years of age, or 0 to 3 for subjects
             greater than or equal to 60 to 74 years of age

          -  Subject must have adequate kidney and liver function as described in the protocol

        Exclusion Criteria:

          -  Subject has received treatment with the following hypomethylating agent and/or chemo
             therapeutic agent for for an antecedent hematologic disorder (AHD) (Subjects may have
             been treated with other agents for AHD i.e., Myelodysplastic syndrome [MDS])

          -  Subject has history of Myeloproliferative Neoplasm (MPN).

          -  Subject has favorable risk cytogenetics as categorized by the National Comprehensive
             Cancer Network Guidelines Version 2, 2014 for AML.

          -  Subject has t(8;21), inv(16), t(16;16) or t(15;17) karyotype abnormalities.

          -  Subject has acute promyelocytic leukemia.

          -  Subject has known active central nervous system involvement with AML.

          -  Subject has received a strong and/or moderate CYP3A inducer within 7 days prior to the
             initiation of study treatment.

          -  Subject has a history of other malignancies prior to study entry, with the exception
             of:

               -  Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of
                  breast;

               -  Basal cell carcinoma of the skin or localized squamous cell carcinoma of the
                  skin;

               -  Previous malignancy confined and surgically resected (or treated with other
                  modalities) with curative intent.

          -  Subject has a white blood cell count > 25 × 10^9/L. Note: Hydroxyurea is permitted to
             meet this criterion.